ACR PI-RADs guidelines suggest anti-spasmodic agents may be beneficial for some patients during multi-parametric prostate MRI (mpMRI). Recent evidence suggests that the anti-spasmodic scopolamine butylbromide improves image quality on mpMRI. However, no studies have evaluated intramuscular (IM) injected glucagon. This retrospective IRB approved single-center study performed data-mining of 2595 mpMRI radiology reports (693 with glucagon) and subjective image quality assessment of 63 mpMRI exams (32 with glucagon). No significant benefit of IM glucagon for prostate evaluation was found on mpMRI. Our findings suggest that the risks associated with IM glucagon (medication side effects, patient discomfort, cost) may outweigh any benefits.
This abstract and the presentation materials are available to members only; a login is required.